• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Consumer Cyclical·600421.SS
Share

Hubei Huarong Holding Co.,Ltd. Stocks

CN¥ 0.24Last Updated 25.06.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

CN¥ 6.93M

CN¥ 0.24
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hubei Huarong Holding Co.,Ltd. is a pharmaceutical enterprise primarily engaged in the manufacturing and distribution of medicinal products across China. Its core pharmaceutical offerings notably feature Gucining Capsules and Huoxue Tongmai Capsules. Beyond its traditional drug production, the company also actively develops biological products, novel pharmaceuticals, environmental protection solutions, and agricultural goods, along with the technologies supporting these areas. The organization was formerly known as Hubei Yangfan Holding Co., Ltd. before officially adopting its current name, Hubei Huarong Holding Co.,Ltd., in November 2020. Established in 1997, the firm maintains its main operational base in Wuhan, China.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 16:00

"There Aren't Enough IT Budgets to Go Around": What Does IBM's Historic Plunge Mean for the Stock Market?

15.07.2026 15:46

Morning in New York: New inflation data will set the tone for trading

15.07.2026 14:33

Where to Invest $1,000 Right Now: 4 Stocks to Consider in the Third Quarter

15.07.2026 13:49

Apple has found a startup that reduces the size of AI models. This could help it improve Siri

15.07.2026 11:45

HSBC has named Kaspi shares its top pick for July. Why does it expect them to rise by a third?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026